Bioequivalence revisited
Author:
- 1 January 1992
- journal article
- research article
- Published by Wiley in Statistics in Medicine
- Vol. 11 (13) , 1777-1788
Abstract
The FDA permits marketing of a generic formulation of a drug G for the same indications as a standard preparation S if one can show that G is bioequivalent to S. Present implementation requires convincing evidence that the population mean difference in bioavailability (drug exposure) between the two preparations lies within specified bounds. The basis for this standard does not appear to involve a comprehensive model for the dose‐response relationship, or consideration of clinical issues, notably (i) whether a patient is to commence on the drug or to switch from an established regimen to a new one; or (ii) that the risk of inequivalence relates to uncertainty of outcome. In this paper, I propose a comprehensive model for dose response and a tentative model for risk that addresses these issues. Specifically, I propose two new measures of bioequivalence which are based on these models, which differ in the two clinical circumstances above, and which respond to both bias and variance of outcome. I present two examples, and some simulations of the application of the new measures.Keywords
This publication has 24 references indexed in Scilit:
- Consideration of individual bioequivalenceJournal of Pharmacokinetics and Biopharmaceutics, 1990
- Application of NONMEM to routine bioavailability dataJournal of Pharmacokinetics and Biopharmaceutics, 1990
- A comparison of the Two One-Sided Tests Procedure and the Power Approach for assessing the equivalence of average bioavailabilityJournal of Pharmacokinetics and Biopharmaceutics, 1987
- Maximum Likelihood Computations with Repeated Measures: Application of the EM AlgorithmJournal of the American Statistical Association, 1987
- METHOTREXATE SYSTEMIC CLEARANCE INFLUENCES PROBABILITY OF RELAPSE IN CHILDREN WITH STANDARD-RISK ACUTE LYMPHOCYTIC LEUKAEMIAThe Lancet, 1984
- Implications of intraindividual variability in bioavailability studies of furosemideEuropean Journal of Clinical Pharmacology, 1984
- Evaluation of the absorption from some commercial enteric-release theophylline productsJournal of Pharmacokinetics and Biopharmaceutics, 1980
- Pharmacokinetics of digoxin: Relationship between response intensity and predicted compartmental drug levels in manJournal of Pharmacokinetics and Biopharmaceutics, 1979
- Use of Statistical Methods in Evaluation of In Vivo Performance of Dosage FormsJournal of Pharmaceutical Sciences, 1973
- Use of Confidence Intervals in Analysis of Comparative Bioavailability TrialsJournal of Pharmaceutical Sciences, 1972